Catalent, Inc. (NYSE:CTLT) Receives Consensus Rating of “Hold” from Analysts
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...
Catalent’s Biologics Underperformance and PCH Stability Lead to Hold Rating
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
BioSpace16h
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up
CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...